News | December 18, 2023
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
There has been no loss or injury to human life
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
